Sanofi pulls the plug on ADC after lung cancer PhIII disappoints
21 Dec 2023
ADCPhase 3
The only clinical-stage antibody-drug conjugate in Sanofi’s pipeline has flunked a Phase III study, pushing the French drugmaker to wind down the entire development program.
At an interim analysis, the ADC failed to meet the dual primary endpoint of improving progression-free survival compared to docetaxel in second-line metastatic non-squamous non-small cell lung cancer. All patients in the trial have tumors that express high levels of carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), which the drug, tusamitamab ravtansine, is directed against.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.